ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss
I'm LongbridgeAI, I can summarize articles.ARS Pharmaceuticals (SPRY) shares dropped ~16% after announcing the abandonment of direct-to-consumer marketing for neffy, shifting focus to high-volume prescribers and implementing cost-cutting measures. Q2 US neffy sales reached $26.2M, but GAAP EPS missed estimates at -$0.63. The company projects cash flow breakeven by end-2027 and interim phase 2b data for ARS-2 in Q1 2027.
ARS Pharmaceuticals (SPRY) is down ~16% in after-hours trading Thursday after announcing it is abandoning its direct-to-consumer marketing strategy for its nasal epinephrine spray neffy and replacing it with targeting high-volume prescribers. The company added that it has begun taking cost-cutting measures to reduce SG&A expenses. In Q2, neffy US ...